Page 3 - Nasdaq Cmpx News Today

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz acquired 20,000 shares of the business’s stock in a transaction dated Wednesday, June 1st. The stock was acquired at an average cost of $3.03 per share, with a total value of $60,600.00. Following the completion of the transaction, the chief executive officer now owns […]

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 231,400 shares, a growth of 82.2% from the April 30th total of 127,000 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average […]

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) have been given a consensus rating of “Buy” by the nine research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1-year price […]

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...